Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells

  title={Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells},
  author={Mitsutoshi Yamada and Bjarki Johannesson and Ido Sagi and Lisa C Burnett and Daniel H. Kort and Robert W. Prosser and Daniel Paull and Michael W. Nestor and Matthew Freeby and Ellen Greenberg and Robin Goland and Rudolph L. Leibel and Susan L. Solomon and Nissim Benvenisty and Mark V. Sauer and Dieter Egli},
The transfer of somatic cell nuclei into oocytes can give rise to pluripotent stem cells that are consistently equivalent to embryonic stem cells, holding promise for autologous cell replacement therapy. Although methods to induce pluripotent stem cells from somatic cells by transcription factors are widely used in basic research, numerous differences between induced pluripotent stem cells and embryonic stem cells have been reported, potentially affecting their clinical use. Because of the… 

Can Somatic Cell Nuclear Transfer Produce Human Pluripotent Stem Cells for Regenerative Medicine

Breakthroughs in the methylation of DNA and histones in mice provided insight to a barrier in human embryo development and derivation of embryonic stem cells was successful and tested for pluripotency.

Concise Review: Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer: A Horse in the Race?

Although NT‐ESCs are more difficult to generate than iPSCs, the ability of somatic cell nuclear transfer to replace aged or diseased mitochondria and the closer epigenomic and transcriptomic similarity between NT‐esCs and bona fide ESCs may make NT‐ ESCs superior for future applications in regenerative medicine.

Stem cells: The quest for the perfect reprogrammed cell

It is suggested that human somatic cells can be faithfully reprogrammed to pluripotency by SCNT and therefore might be more appropriate than iPS cells for use in cell replacement therapies.

Pluripotent Stem Cells, Endogenous versus Reprogrammed, a Review

This review outlines the developmental process and differentiative capabilities of endogenous and reprogrammed Pluripotent stem cells; the manufacture and differento-differential capabilities of reprogramed PlurIPotentstem cells; and the inherent characteristics of endogenousand reprogramming stem cells.

The role of the reprogramming method and pluripotency state in gamete differentiation from patient-specific human pluripotent stem cells

The derivation of gametes from patient-specific pluripotent stem cells may provide new perspectives for genetic parenthood for patients currently facing sterility and the role of the stem cell pluripotency state in germ cell differentiation is discussed.

Generation of embryonic stem cells from mouse adipose-tissue derived cells via somatic cell nuclear transfer

It is demonstrated for the first time that ESCs can be generated from the adipose tissue by somatic cell nuclear transfer (SCNT) and it is suggested that ADCs can be a new donor-cell type for potential therapeutic cloning.

Derivation and differentiation of haploid human embryonic stem cells

Diploidy is a fundamental genetic feature in mammals, in which haploid cells normally arise only as post-meiotic germ cells that serve to ensure a diploid genome upon fertilization. Gamete

Reprogramming mechanisms influence the maturation of hematopoietic progenitors from human pluripotent stem cells

It is suggested that genetically identical iPSCs and NT-ESCs could be functionally unequal due to differential transcription and methylation levels acquired during reprogramming.

Teratoma: from spontaneous tumors to the pluripotency/malignancy assay

The standardized teratoma assay should be directed more to the assessment of EC/malignant cell features than of differentiated tissues, especially after a unique case of human therapy with neural stem cells was found to lead to malignancy.



Human oocytes reprogram somatic cells to a pluripotent state

The development of human oocytes after genome exchange arrests at late cleavage stages in association with transcriptional abnormalities, demonstrating the feasibility of reprogramming human cells using oocytes and identifying removal of the oocyte genome as the primary cause of developmental failure after genome Exchange.

Nuclear transfer into mouse oocytes.

This movie and the accompanying protocol are intended to help learning nuclear transfer in the mouse, a method initially developed in the group of Prof. Yanagimachi (WAKAYAMA et al. 1998).

Epigenetic memory in induced pluripotent stem cells

It is observed that low-passage induced pluripotent stem cells (iPSCs) derived by factor-based reprogramming of adult murine tissues harbour residual DNA methylation signatures characteristic of their somatic tissue of origin, which favours their differentiation along lineages related to the donor cell, while restricting alternative cell fates.

Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells

Comparisons of the in vitro neural differentiation of 40 hiPSCs and 10 human embryonic stem cells showed that seven hiPSC clones retained a significant number of undifferentiated cells even after neural differentiation culture and formed teratoma when transplanted into mouse brains.

Equivalency of Nuclear Transfer‐Derived Embryonic Stem Cells to Those Derived from Fertilized Mouse Blastocysts

Compared to blastocyst‐derived ESCs, the similarities of NT‐ESCs and ESCs indicate that murine therapeutic cloning by somatic cell NT can provide a reliable model for preclinical stem cell research.

Somatic coding mutations in human induced pluripotent stem cells

It is shown that 22 human induced pluripotent stem (hiPS) cell lines reprogrammed using five different methods each contained an average of five protein-coding point mutations in the regions sampled, and that hiPS cells acquire genetic modifications in addition to epigenetic modifications.

Reprogramming within hours following nuclear transfer into mouse but not human zygotes.

Mouse zygotes reprogrammed the somatic cell genome to a pluripotent state within hours after transfer, suggesting that there may be a previously unappreciated barrier to successful human nuclear transfer and that future studies could focus on the requirements for genome activation.

Derivation of cloned human blastocysts by histone deacetylase inhibitor treatment after somatic cell nuclear transfer with β-thalassemia fibroblasts.

Treatment of SCNT embryos with 5  nM TSA for 10  h following activation incubation increased the developmental competence of human SC NT embryos constructed from β-thalassemia fibroblast cells, and improved the acetylation of histone H3 at lysine 9 in a manner similar to that observed in in vitro fertilized embryos.